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Abstract: Taurine is a nonproteinogenic amino sulfonic acid in mammals. Interestingly, skeletal
muscle is unable to synthesize taurine endogenously, and the processing of muscular taurine
changes throughout ageing and under specific pathophysiological conditions, such as muscular
dystrophy. Ageing and disease are also associated with altered iron metabolism, especially when
there is an excess of labile iron. The present study addresses the question of whether taurine
connects cytoprotective effects and redox homeostasis in a previously unknown iron-dependent
manner. Using cultured differentiated C2C12 myotubes, the impact of taurine on markers of lipid
peroxidation, redox-sensitive enzymes and iron-related proteins was studied. Significant increases
in the heme protein myoglobin and the iron storage protein ferritin were observed in response to
taurine treatment. Taurine supplementation reduced lipid peroxidation and BODIPY oxidation
by ~60 and 25%, respectively. Furthermore, the mRNA levels of redox-sensitive heme oxygenase
(Hmox1), catalase (Cat) and glutamate-cysteine ligase (Gclc) and the total cellular glutathione content were
lower in taurine-supplemented cells than they were in the control cells. We suggest that taurine may
inhibit the initiation and propagation of lipid peroxidation by lowering basal levels of cellular stress,
perhaps through reduction of the cellular labile iron pool.
Keywords: skeletal muscle; labile iron pool; myoglobin; glutathione; BODIPY
1. Introduction
Iron plays an important role in physiological and pathophysiological biochemical processes.
The pool of iron in the body consists of heme proteins (hemoglobin, myoglobin and heme enzymes),
transport and storage proteins (transferrin and ferritin) and functional iron-sulfur cluster proteins
(e.g., complexes I, II and III of the respiratory chain) [1,2]. Iron-dependent proteins are important for
enabling cellular growth and proliferation [3,4] and energy metabolism [5,6]. The majority of cellular
iron is bound to proteins, and only a small proportion (1–2%) is free. The so-called labile iron is
chelatable and includes both ferrous (Fe2+) and ferric (Fe3+) ions [7]. Labile iron acts as a catalyst for the
generation of reactive oxygen species (ROS), through, for example, the Fenton reaction (Fe2+ + H2O2
→ Fe3+ + OH− + OH•), which forms highly reactive hydroxyl radical (OH•) species. Reactive oxygen
species such as OH• promote lipid peroxidation [8] and oxidative damage to other biomolecules.
Taurine is a nonproteinogenic amino sulfonic acid that is either endogenously produced from the
degradation of methionine and cysteine [9,10] or is derived from dietary sources of animal origin [11].
For chemical structure see Scheme 1.
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Scheme 1. Chemical structure of taurine showing its two functional groups, the amino group and the 
sulfonic acid group. Taurine is zwitterionic at an isoelectric point of 5.12 [12]. The molecular weight 
of taurine is 125.15 g/mol and the molecular formula is C2H7NO3S [13]. 
Excitatory tissues such as the retina, brain, heart and skeletal muscle [12,14,15] contain especially 
high concentrations of taurine. These tissues have a high metabolic rate and are highly vulnerable to 
oxidative damage. Moreover, aging might alter taurine homeostasis in several tissues of laboratory 
rodents, as shown in Table 1. 
Table 1. Relative changes (%) in tissue taurine/taurine metabolite concentrations in aged compared 












>70% decrease [16] 
C57 BL/6J 
mice 





Heart muscle ~55% increase 
Brain ~35% decrease 
Liver No change 
Kidney No change 
Blood No change 
Long-Evans 
rats 






[19] Kidney ~30% decrease 
Brain (Cerebellum) ~14% decrease 
Wistar rats 




Blood No change 
Skeletal muscle is the main storage site for taurine in the mammalian body. Interestingly, in 
humans [21] and other species [22–25], taurine was shown to be substantially higher in oxidative 
type I compared to glycolytic type II muscles. Muscle senescence and atrophy are accompanied by 
declining cellular taurine concentrations [20,26,27], altered iron metabolism and increased oxidative 
injury [28,29]. Furthermore, ageing and disease are also associated with altered iron metabolism, 
especially when there is an excess of labile iron. Therefore, a causal relationship between taurine and 
iron metabolism in muscle health and disease is plausible. Research in recent decades has revealed 
that taurine exhibits cytoprotective properties and prevents tissues from oxidative injury [10]. 
Potential molecular mechanisms of taurine, such as free-radical scavenging activity [15,30], induction 
of antioxidative defense mechanisms [31–33] and diminished generation of reactive oxygen species 
(ROS) [34], have been proposed. Moreover, in iron-overload rodent models, dietary taurine reduced 
myocardial [35] and hepatic [36,37] tissue injury caused by oxidative stress. The induction of 
antioxidative defense mechanisms, such as higher activity of antioxidative enzymes or elevated 
glutathione levels, was suggested to underlie the cytoprotective properties of taurine [35,36]. Apart 
from that, little is known about the potential direct effects taurine may exert on catalytic transition 
metals such as iron. One possibility that has been discussed by Petrova and Neudachina is that 
taurine may have the ability to physically bind metal ions [38]. However, experimental evidence of 
the physical interaction between taurine and iron has not yet been provided. Muscle cells are 
particularly suitable for studying the molecular effects of taurine due to the lack of key enzymes 
required for endogenous taurine synthesis. In the present study, differentiated C2C12 mouse 
myoblasts were used to examine the molecular effects of taurine on cellular iron and redox 
homeostasis. 
Scheme 1. Chemical structure of taurine showing its two functional groups, the amino group and the
sulfonic acid group. Taurine is zwitterionic at an isoelectric point of 5.12 [12]. The molecular weight of
taurine is 125.15 g/mol and the molecular formula is C2H7NO3S [13].
Excitatory tissues such as the retina, brain, heart and skeletal muscle [12,14,15] contain especially
high concentrations of taurine. These tissues have a high metabolic rate and are highly vulnerable to
oxidative damage. Moreover, aging might alter taurine homeostasis in several tissues of laboratory
rodents, as shown in Table 1.
Table 1. Relative changes (%) in tissue taurine/taurine metabolite concentrations in aged compared to
young control laboratory rodents.
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Skeletal muscle is the main storage site for taurine in the mammalian body. Interestingly,
in humans [21] and other species [22–25], taurine was shown to be substantially higher in oxidative
type I compared to glycolytic type II muscles. Muscle senescence and atrophy are accompanied by
declining cellular taurine concentrations [20,26,27], altered iron metabolism and increased oxidative
injury [28,29]. Furthermore, ageing and disease are also associated with altered iron metabolism,
especially when there is an excess of labile iron. Therefore, a causal relationship between taurine
and iron metabolism in muscle health and disease is plausible. Research in recent decades has
revealed that taurine exhibits cytoprotective properties and prevents tissues from oxidative injury [10].
Potential molecular mechanisms of taurine, such as free-radical scavenging activity [15,30], induction
of antioxidative defense mechanisms [31–33] and diminished generation of reactive oxygen species
(ROS) [34], have been proposed. Moreover, in iron-overload rodent models, dietary taurine reduced
myocardial [35] and hepatic [36,37] tissue injury caused by oxidative stress. The induction of
antioxidative defense mechanisms, such as higher activity of antioxidative enzymes or elevated
glutathione levels, was suggested to underlie the cytoprotective properties of taurine [35,36]. Apart from
that, little is known about the potential direct effects taurine may exert on catalytic transition metals
such as iron. One possibility that has been discussed by Petrova and Neudachina is that taurine may
have the ability to physically bind metal ions [38]. However, experimental evidence of the physical
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interaction between taurine and iron has not yet been provided. Muscle cells are particularly suitable
for studying the molecular effects of taurine due to the lack of key enzymes required for endogenous
taurine synthesis. In the present study, differentiated C2C12 mouse myoblasts were used to examine
the molecular effects of taurine on cellular iron and redox homeostasis.
2. Materials and Methods
2.1. Cell Culture
C2C12 cells were purchased from IAZ (Institute for applied cell culture, Munich, Germany).
Myoblasts were maintained in Dulbecco’s modified Eagle’s medium (DMEM, high glucose 4.5 g/L,
P04-03590, PANTM Biotech GmbH) supplemented with 20% (v/v) fetal bovine serum (FBS) and 1%
Pen/Strep. Final experiments were conducted with differentiated myotubes. To this end, cells were
seeded into cell culture plates and proliferated until they reached approximately 90% confluence
(~48 h later). Myogenesis was initiated by switching the growth medium (20% FBS) to differentiation
medium containing 2% horse serum. The differentiation medium was refreshed every 24 h. After four
days of differentiation cells expressed the intended morphology of fused myotubes. At day four
the differentiation medium was supplemented with taurine or respective other substances. If not
indicated otherwise, the abbreviation TAUR means that cells were treated with 5 mmol/L taurine in
differentiation medium.
2.2. Cell Viability Test
Cell viability was estimated via neutral red uptake assay [39]. Cells were seeded in 24-well plates
and were differentiated as described in the “Cell culture” section. C2C12 myotubes were incubated
with taurine (Sigma Aldrich, T0625, Darmstadt, Germany) in a range of concentrations (1–250 mmol/L)
and 10% ethanol as the positive control to induce cytotoxicity. After 24 h, the cells were incubated with
1% neutral red solution (Carl Roth GmbH, Karlsruhe, Germany) for 2 h. Afterwards, cells were lysed
in a discoloration solution, and adsorption of neutral red was measured with a microtiter plate reader
at 540 nm (iEMS Reader MF, MTX Labsystem Inc.,Vienna USA).
2.3. Thiobarbituric Acid Reactive Substances (TBARS)
Lipid peroxidation was determined by colorimetric TBARS assays according to the method
described by Kai (1978) [40]. Differentiated myotubes were cultured in 6-well plates and treated with
5 mmol/L taurine, 250 µM Trolox or control medium for 48 h. Fresh treatments replaced the old
after 24 h. Cells were harvested by scraping with Dulbecco’s phosphate-buffer saline (DBPS) on ice.
Total protein content was estimated using the bicinchoninic acid (BCA) method (PierceTM BCA Protein
Assay, Thermo Scientific, Waltham, USA). Proteins of the remaining cell suspension were precipitated
with 5% trichloroacetic acid (TCA). The supernatant (200 µL) was stabilized in 20 µL of 0.5% mixture
of sodium docecyl sulfate (SDS)-butylated hydroxytoluene (BHT), and an equivalent volume of 1%
thiobarbituric acid (TBA) was added. The mixture was incubated for 20 min at 99 ◦C. After cooling on
ice, 1 mL of butanol was added to the mixture to extract the pink trimetin colorant. The supernatant was
transferred to a 96-well plate in triplicate. Fluorescence (λex = 520 nm/λem = 560 nm) was measured
with a microplate reader. Tetraethoxypropane (Sigma Aldrich, Darmstadt, Germany) was used as an
external standard.
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2.4. Lipid Peroxidation Determined by BODIPY Assay
C11-BODIPY (581/591) (Life Technologies, D-3861, Darmstadt, Germany) is a fluorescent dye that
can be used as a lipid peroxidation sensor. This fatty acid analogue is lipophilic and incorporates
into biomembranes. After being oxidized, the fluorescent properties of C11-BODIPY shift due to the
change from the reduced (λex = 540 nm/λem = 595 nm) to the oxidized (λex = 480 nm/λem = 520 nm)
state. The adjusted index of BODIPY oxidation was calculated as follows:
Adjusted Index = EmOx/(EmOx + EmRed)
C2C12 cells were seeded in black-walled, clear-bottom 96-well cell culture plates. C2C12 cells
were first differentiated as described previously. Prior to the addition of BODIPY, cells were incubated
with medium (CON) or taurine (TAUR). After 24 h, the medium was removed, and the cells were
rinsed and treated with 10 µM BODIPY in medium for 30 min. Then, the medium was removed, and
the cells were exposed to either 2 µmol/L iron(II) sulfate (Fe2+, Merck, Germany), 80 µmol/L cumene
hydroperoxide (CumOOH, Sigma Aldrich, Germany) or a mixture of 2 µmol/L Fe2+ and 80 µmol/L
CumOOH in DPBS at 37 ◦C for 1 h. Afterwards, cells were washed with DBPS, and fluorescence of
adherent cells was measured using a microplate reader (TECAN infinite F200, Grödig, Austria).
2.5. Cellular Total Glutathione
Cells were treated without (CON) or with 5 mmol/L taurine (TAUR) for 24 h. After the
medium was removed, adherent cells were washed with DPBS and lysed in 10 mM HCl by
being subjected to freeze-thaw cycles. The total protein content in the lysates was determined
by the BCA method. The remaining lysates were used for GSH detection after proteins were
precipitated with an equal volume of 6.5% sulfo salicylic acid (SSA). The GSH concentration was
measured according to the enzymatic recycling method described by [41,42]. In short, GSH is
oxidized by 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) to form glutathione disulphide (GSSG) and
5’-thio-2-nitrobenzoic acid (TNB). The latter can be measured at 412 nm. In the presence of nicotinamide
adenine dinucleotide phosphate (NADPH), GSSG can be recycled by GSH reductase. Here, 20 µL of
standards/samples were transferred to a 96-well plate and incubated for 5 min with 200 µL of reagent
mix (1 mmol/L DTNB and 0.34 mmol/L NADPH in stock buffer). Then, 40 µL of GSH-reductase
(8.5 IU/mL) was quickly added to each well, and adsorption was measured kinetically every 20 s for
2 min at 415 nm (iEMS Reader MF, MTX Labsystem Inc., Vienna, USA).
2.6. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)
Differentiated myotubes were incubated in control media in the absence of taurine (CON) or with
5 mmol/L taurine (TAUR) for 6 h. Afterwards, cells were harvested with peqGOLD TriFast (VWR
International GmbH, Darmstadt, Germany), and RNA was isolated according to the manufacturer’s
instructions. Sample RNA concentrations and quality were assessed with a Nano Drop 2000 UV-Vis
spectrophotometer (Thermo Fisher Scientific GmbH, Life Technologies™, Darmstadt, Germany). Gene
expression was analyzed via qRT-PCR with a SensiFASTTM SYBR® No-ROX One-Step Kit (Bioline
GmbH, Luckenwalde, Germany) using a Rotorgene 6000 cycler (Corbett Life Science, Sydney, Australia).
The primer sequences used for the quantification of the target genes are listed in Table 2. Relative
mRNA levels were quantified as the ratio between the target gene and a housekeeping gene (Ap3d1).
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Table 2. Nucleotide sequences of primers used for quantitative real-time PCR. Primer pairs are listed
as forward (F) and reverse (R) with the corresponding annealing temperature (Ta) that was determined
individually for all pairs.





































Ap3d1, Adaptor-related protein complex 3, delta 1 subunit; Bola3, BolA Family Member 3; Cat, Catalase; Fth,
Ferritin heavy chain; Ftl, Ferritin light chain; Gclc, Glutamate-cysteine ligase (catalytic subunit); Glxr5, Glutaredoxin;
Hmox1, Heme oxygenase 1; Nfu1, Iron-Sulfur Cluster Scaffold; Nubpl, Nucleotide Binding Protein Like; Taut, taurine
transporter; Tfr, transferrin receptor.
2.7. Western Blotting
Cultivated C2C12 cells were differentiated and treated with CON or TAUR for 24 h. Cells were
harvested on ice with a RIPA-PIC-PhosSTOP (100:1:10) buffer mixture. After cell lysis and centrifugation
of the sample, the supernatants quantified via the BCA method and were then subjected to western
blotting. For western blotting, 30µg of each sample was loaded on MINI PROTEAN® TGX-Stain-FreeTM
precast gels (BioRad, Munich, Germany) and then was separated via gel electrophoresis. Afterward, the
proteins were transferred to a membrane (Immuno-Blot® PVDF Membrane for Protein Blotting, BioRad,
Munich, Germany), blocked with skimmed milk and incubated with primary antibodies overnight.
The following antibodies were used: cytochrome c, 15 kDa (sc-13560, Santa Cruz Biotechnology, Dallas,
USA), ferritin heavy chain 21 kDa (sc-376594, Santa Cruz Biotechnology), ferritin light chain, 19 kDa
(ab69090, Abcam, Berlin, Germany), myoglobin, 17 kDa (D2F5X, Cell Signaling, Leiden, Netherlands),
taurine transporter 65-70 kDa (AB5414P, Merck, Darmstadt, Germany) and total OXPHOS antibody
cocktail (ab110413, Abcam). For the taurine transporter, the target band was detected at approximately
140 kDa, indicating a dimeric structure. Afterwards, membranes were incubated with a secondary
antibody for 1 hour, and bands were visualized using an enhanced chemiluminescence (ECL) substrate
and a ChemiDoc XRS system (both BioRad). The signal of targeted bands was densitometrically
analyzed and normalized against the total protein load. Image Lab Software 5.2.1 (BioRad, Munich,
Germany) was used for protein quantification.
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2.8. Catalase Activity
The catalase activity was determined according to Johansson and Borg (1988) [43]. The assay
is based on the catalase driven oxidation of methanol in the presence of hydrogen peroxide to
produce formaldehyde. Formaldehyde reacts with 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole
(Purpald, Sigma Aldrich, Darmstadt, Germany). After addition of alkaline potassium periodate solution,
the formaldehyde-purpald adduct oxidizes and develops a color that is detected spectrophotometrically
at 540 nm.
For cell culture experiments differentiated myotubes were incubated in 6-well plates with CON
and TAUR. After 24 h, cells were sonicated in 200 µL of phosphate buffer and supernatant was used for
the determination of catalase activity and total protein quantification via BCA method. For the present
study, 30 µL samples and 66 µL assay mix (phosphate buffer, methanol, hydrogen peroxide) were
incubated at room temperature for 20 min before the addition of potassium periodate. The catalase
activity was calculated using a dilution series produced by purified catalase from bovine liver (Sigma
Aldrich, Darmstadt, Germany).
2.9. Statistical Analysis
Statistical analyses were conducted using GraphPad PRISM software (San Diego, CA, USA) and
IBM SPSS Statistics 24 (Ehningen, Germany). For statistical hypothesis tests, groups were analyzed for
normality of the distribution (Kolmogorov-Smirnov and Shapiro-Wilk tests). In the case of normally
distributed data, Levene’s test was conducted to assess the homogeneity of variances. If the null
hypothesis was rejected (Levene’s test indicated it was not significant), for multiple comparison a
one-way analysis of variance (ANOVA) with a one-sided Tukey test as post hoc analysis was performed.
If the null hypothesis was confirmed (Levene’s test indicated significance), the Games-Howell post hoc
test was used. For comparison of two groups a t-test was performed with normal distributed data
while the Mann–Whitney U test was chosen if data did not pass the test of normal distribution.
3. Results
3.1. The Impact of Taurine on Cell Viability and Cellular Taurine Management
The cell viability of medium control (CON) cells was set as 100%. Taurine tended to be cytotoxic
at concentrations ≥250 mmol/L (Figure 1a). Lower taurine concentrations (5–50 mmol/L) increased
the absorbance of viable at 540 nm up to 160% compared to control. Microscopy images (Figure 1c)
illustrate the morphology of already differentiated myotubes after incubation with 10% ethanol (EtOH)
and different taurine concentrations. The control cells exhibited the typical morphology of long
myotubes that were formed during four days myogenesis by fusion of C2C12 myoblast. The treatment
with 5 and 100 mmol/L taurine did not affect cell morphology compared to control cells. The positive
cytotoxicity control EtOH as well as the highest concentration of 250 mmol/L taurine seemed to reverse
the differentiation status of the myotubes which is reflected by cell fragmentation. Moreover, EtOH
induced the removal the adherent cells from the plate and their agglomeration within the medium.
The lowest taurine concentration that enhanced the cell viability (5 mmol/L) was used for further
experiments and is abbreviated hereafter as TAUR. Furthermore, the mRNA levels of the gene encoding
the taurine transporter (Taut) were significantly downregulated, while the TAUT protein levels were
not affected by taurine treatment (Figure 1b, Figure S1a).
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Figure 1. Taurine (TAUR) was not cytotoxic at concentrations of up to 100 mmol/L (a) Cell viability 
after 24 h was determined by the uptake of neutral red by taurine-supplemented (1–250 mmol/L) 
myotubes and untreated control (CON) myotubes. Ethanol (10%) was used as the positive control to 
induce cytotoxicity. The data are shown as the means + SEM (n = 6–9). (b) Compared to CON, TAUR 
decreased the mRNA levels of the taurine transporter (TAUT), but TAUT protein levels remained 
unchanged. TAUT protein levels were quantified densitometrically and normalized according to total 
protein per lane. A representative section of the target bands and corresponding total protein bands 
visualized by UV are shown. (c) Optical microscopy images (200×) of differentiated myotubes show 
morphological changes and cell fragmentation induced by treatment with EtOH and the highest 
taurine concentration (250 mmol/L), whereas cells incubated with 5 mmol/L taurine did not differ 
from CON cells. The data are shown as the means + SEM (n = 3 for taurine and TAUT analysis; n = 6 
for Taut mRNA experiments). * Indicates significant differences compared to CON; p < 0.05. 
3.2. The Impact of Taurine on Celluar Redox-Homeostasis 
Cellular lipid peroxidation (LPO) was determined using TBARS and BODIPY assays (Figure 
2a,b). Under basal conditions, taurine significantly prevented the generation of secondary LPO 
products (TBARS) by approximately 60% within 48 h. For the BODIPY assay, CON-and TAUR-
pretreated cells were loaded with the fluorescent dye C11 BODIPY (581/591), a fatty acid analogue 
that incorporates into the cell membrane. BODIPY oxidation was measured under basal conditions 
(without any exogenous stressors) and after 60 min of supplementation with iron (Fe2+) and cumene 
hydroperoxide (CumOOH). In general, Fe2+ itself did not affect BODIPY oxidation, while BODIPY 
oxidation was induced by CumOOH. Taurine significantly counteracted CumOOH-induced 
BODIPY oxidation (−25%). In addition, the mRNA levels of genes encoding redox-sensitive enzymes 
were quantified in control and taurine-treated cells. The mRNA levels of heme oxygenase 1 (Hmox1), 
catalase (Cat) and glutamate-cysteine ligase catalytic subunit (Gclc) were downregulated in response 
to taurine treatment (Figure 2c). In line with the decline of the Cat mRNA level, the catalase activity 
was significantly lower in taurine-treated compared to control cells. In addition, the reduced Gclc 
mRNA level detected in taurine-treated cells, was accompanied by an approximately 50% drop of the 
total cellular glutathione level, which consists of reduced (GSH) and oxidized (GSSG) glutathione 
(Figure 2d). 
Figure 1. Taurine (TAUR) was not cytotoxic at concentrations of up to 100 mmol/L (a) Cell viability
after 24 h was determined by the uptake of neutral red by taurine-supplemented (1–250 mmol/L)
myotubes and untreated control (CON) myotubes. Ethanol (10%) was used as the positive control to
induce cytotoxicity. The data are shown as the means + SEM (n = 6–9). (b) Compared to CON, TAUR
decreased the mRNA levels of the taurine transporter (TAUT), but TAUT protein levels remained
unchanged. TAUT protein levels were quantified densitometrically and normalized according to total
protein per lane. A representative section of the target bands and corresponding total protein bands
visualized by UV are shown. (c) Optical microscopy images (200×) of differentiated myotubes show
morphological changes and cell fragmentation induced by treatment with EtOH and the highest taurine
concentration (250 mmol/L), whereas cells incubated with 5 mmol/L taurine did not differ from CON
cells. The data are shown as the means + SEM (n = 3 for taurine and TAUT analysis; n = 6 for Taut
mRNA experiments). * Indicates significant differences compared to CON; p < 0.05.
3.2. The Impact of Taurine on Celluar Redox-Homeostasis
Cellular lipid peroxidation (LPO) was determined using TBARS and BODIPY assays (Figure 2a,b).
Under basal conditions, taurine significantly prevented the generation of secondary LPO products
(TBARS) by approximately 60% within 48 h. For the BODIPY assay, CON-and TAUR-pretreated cells
were loaded with the fluorescent dye C11 BODIPY (581/591), a fatty acid analogue that incorporates
into the cell membrane. BODIPY oxidation was measured under basal conditions (without any
exogenous stressors) and after 60 min of supplementation with iron (Fe2+) and cumene hydroperoxide
(CumOOH). In general, Fe2+ itself did not affect BODIPY oxidation, while BODIPY oxidation was
induced by CumOOH. Taurine significantly counteracted CumOOH-induced BODIPY oxidation
(−25%). In addition, the mRNA levels of genes encoding redox-sensitive enzymes were quantified in
control and taurine-treated cells. The mRNA levels of heme oxygenase 1 (Hmox1), catalase (Cat) and
glutamate-cysteine ligase catalytic subunit (Gclc) were downregulated in response to taurine treatment
(Figure 2c). In line with the decline of the Cat mRNA level, the catalase activity was significantly lower
in taurine-treated compared to control cells. In addition, the reduced Gclc mRNA level detected in
taurine-treated cells, was accompanied by an approximately 50% drop of the total cellular glutathione
level, which consists of reduced (GSH) and oxidized (GSSG) glutathione (Figure 2d).
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CYTC were slightly increased, and compared to the control, the MB protein amount was 1.7 times 
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Figure 2. Taurine (TAUR) reduced markers for lipid peroxidation (LPO) and cellular redox homeostasis.
(a) TAUR reduced the level of secondary LPO products measured as thiobarbituric acid reactive
substances (TBARS). (b) To examine LPO under basal and stress conditions, myotubes were treated
with the fluorescent dye C11 (undecanoic acid)-BODIPY 581/591, and then DPBS buffer was added
in the absence or presence of 2 µmol/L iron(II) sulfate (Fe2+) and 80 µmol/L cumene hydroperoxide
(CumOOH). TAUR counteracted CumOOH-induced lipid peroxidation. BODIPY oxidation was
determined by the ratio of oxidized to total BODIPY (oxidized + reduced) measured as fluorescence
intensity. (c) The mRNA levels of heme oxygenase 1 (Hmox1), catalase (Cat) and glutamate-cysteine
ligase, catalytic subunit (Gclc) were downregulated after 6 h of treatment with TAUR. (d) Catalase
activity was significantly downregulated due to 24 h of incubation with TAUR compared to CON.
(e) TAUR decreased the cellular content of total glutathione (tGSH = GSH + GSSG) under basal
conditions. The data are shown as the means + SEM (n ≥ 6). * Indicates significant differences compared
with CON; p < 0.05. Glutathione (GSH); glutathione disulfide (GSSG).
3.3. The Impact of Taurine on Iron-Related Proteins
The protein levels of four iron-related proteins were analyzed via western blotting (Figure 3a,
Figure S1b–e). The light chain ferritin isoform (FTL), which is involved in cellular iron storage,
increased more than two-fold in response to taurine treatment. However, the heavy chain ferritin
isoform (FTH) was not affected by taurine supplementation. The protein levels of the heme protein
CYTC were slightly increased, and compared to the control, the MB protein amount was 1.7 times
higher upon taurine incubation. The relative mRNA levels of Ftl, Fth and Tfr were analyzed, since
their expression is tightly regulated by intracellular iron availability (Figure 3b). As a positive control,
C2C12 cells were treated with 2 µmol/L Fe2+-sulfate. Iron-treated myotubes exhibited significantly
higher Ftl mRNA expression, while Tfr mRNA expression was downregulated. Taurine did not affect
Ftl, Fth or Tfr mRNA levels compared to those of the control. Furthermore, protein levels of specific
subunits representing the presence of mitochondrial oxidative phosphorylation complexes were not
affected by the taurine treatment (Figure 3c, Figure S1f). In addition, the mRNA levels of four genes
encoding proteins that are involved in iron-sulfur-cluster (ISC) protein synthesis and assembly were
quantified via qRT-PCR. Taurine supplementation led to a 1.5-fold increase in mRNA levels of the
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Nubpl gene. The mRNA levels of genes encoding for Nfu1, Bola3 and Glxr5 did not differ between
control and taurine treated cells (Figure 3d).Anti xidants 2020, 9, x FOR PEER REVIEW 9 of 15 
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Figure 3. Taurine enhanced ferritin and myoglobin protein levels. (a) The mean protein levels of
ferritin light chain (FTL), cytochrome c (CYTC) and myoglobin (MB) were increased after taurine
(TAUR) supplementation. The levels in the untreated control (CON) were set to 1 for each individual
experiment, and the results of TAUR supple entation are given relative to those of CON. Target
band intensity was densitometrically analyzed and normalized by total protein load per lane, as
visualized in a stain-free UV image. Representative pictures of the target bands (FTL, FTH, CYTC
and MB) and the corresponding total protein bands are shown. (b) The mRNA levels of iron-sensitive
genes Ftl, Fth and Tfr were quantified in response to treatment with TAUR and iron (II) sulfate (Fe2+).
Fe2+, which was used as a positive control, significantly enhanced Ftl and decreased Tfr mRNA
levels compared to those of untreated cells. The mRNA levels of Fth were not affected by Fe2+ or
taurine. (c) A representative picture of target bands indicating the subunits of mitochondrial oxidative
phosphorylation (OXPHOS) complexes CI (NADH dehydrogenese), CII (succinate dehydrogenase),
CIII (ubiquinol-cytochrome c reductase), CIV (cytochrome c oxidase) and CV (ATP-Synthase) for CON
and TAUR and the corresponding total protein load are shown. (d) The relative mRNA levels of NFU1
iron-sulfur cluster scaffold (Nfu1), BolA FAMILY MEMBER 3 (Bola3) and glutaredoxin 5 (Glxr5) were
not affected, while nucleotide binding protein like (Nubpl) mRNA was upregulated in response to
taurine supplementation. The data are shown as the means + SD (n = 3) for the protein analysis and
means + SEM (n = 6) for mRNA results. * Indicates a significant difference; p < 0.05.
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4. Discussion
Differentiated C2C12 mouse myotubes were used as a cell culture model to study the impact of
taurine on cellular redox homeostasis and iron metabolism. Since skeletal muscle is not able to synthesize
appropriate amounts of taurine, muscle cells need to take up circulating taurine via active transport to
prevent deficiency symptoms such as impaired muscle function and energy metabolism [44,45]. In the
present study, cultured myotubes were supplied with exogenous taurine via cell culture medium.
Therefore, an appropriate, non-toxic concentration of taurine was initially established by the neutral
red assay. The highest taurine concentration (250 mmol/L) significantly reduced the viability of C2C12
myotubes. Interestingly, taurine concentrations between 5 and 100 mmol/L seemed to enhance the cell
viability compared to control. The neutral red assay provides information on the number of living
cells which were calculated relative to the amount of living control cells. Since control cells were
not exposed to external stress, we suggest that taurine did not prevent the degradation of existing
myotubes but rather re-activates the proliferation of quiescent myoblasts. However, this point needs
further investigation.
Physiological taurine concentrations have already been determined to be approximately 15 to
30 mmol/L in mouse skeletal muscle [46–48]. However, there is a substantial concentration gradient
between intracellular and extracellular mammalian taurine levels in vivo [12,49]. To attain more
physiological extracellular taurine levels, 5 mmol/L taurine was used for further experiments. In vivo,
transcellular taurine transport occurs actively against a concentration gradient [12]. The taurine
transporter (TAUT) is encoded by the solute carrier family 6 member 6 (Slc6a6; Taut) gene. In our
study, Taut mRNA was significantly downregulated (by 50%) in response to supplementation of the
cell culture medium with 5 mmol/L taurine. Accordingly, Han et al. reported on a concentration and
time dependent downregulation of Taut mRNA at physiological extracellular taurine concentrations of
0.05 and 0.5 mmol/L in MDCK kidney cells [50]. Thus, taurine may generally repress the Taut mRNA
expression via negative feedback regulation. However, the TAUT protein levels were not affected,
indicating that the TAUT protein amount may not be exclusively regulated at the transcriptional
level. As observed by others, the TauT activity is tightly regulated and there might be a passive efflux
via volume-sensitive anion channels [51,52]. Furthermore, it cannot be excluded that taurine may
act via extracellular signaling or as taurine-conjugated metabolites such as N-acyl taurine (NATs) or
glutamyltaurine rather than in its free form [53].
The potential antioxidative properties of taurine in cultured C2C12 cells were determined via
TBARS and BODIPY assays. Under basal conditions, long-term taurine treatment (48 h) prevented
the formation of lipid peroxidation products (TBARS) by approximately 60% compared to that of
the control. Furthermore, the role of taurine in the protection of membrane PUFAs against oxidation
was investigated using the fluorescent fatty acid analogue C11-BODIPY (581/591) as the LPO sensor.
The impact of taurine on BODIPY oxidation was tested under basal conditions or after stimulation
with low doses of Fe2+ and CumOOH. BODIPY oxidation was not different between untreated and
taurine-supplemented cells under basal conditions. BODIPY oxidation was significantly increased upon
treatment with CumOOH, an agent propagating LPO in cells; this effect was significantly counteracted
by taurine. Because taurine is a water-soluble molecule, it seems unlikely that it accumulates in the
lipid layer of membranes to directly inhibit the propagation of LPO. On the other hand, CumOOH
is a semi-stable oxidizing agent that has to be “activated” by transition metals such as Fe2+ to form
lipophilic cumoxyl radicals (CumO•) [54,55]. Once it becomes a radical, CumO• attacks unsaturated
fatty acids or other susceptible structures (e.g., BODIPY) within the lipid layer of biomembranes [8].
Thus, taurine supplementation may diminish the intracellular labile iron pool (LIP), and consequently,
reduce the conversion of the semi-stable CumOOH to the more reactive CumO• radical.
In addition to the LPO biomarkers, cellular total glutathione (GSH) was reduced, and mRNA
levels of genes encoding redox-sensitive antioxidative enzymes (Hmox1, Cat and Gclc) were significantly
downregulated in response to taurine. Moreover, the catalase activity was reduced by approximately
40% due to the taurine treatment. These results support our hypothesis that taurine may act via
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suppression of oxygen radical formation (driven by free iron) rather than by upregulating defense
and repair mechanisms induced by oxidatively damaged biomolecules. However, most of the assays
applied in our study relate to unstressed cellular conditions. The presence of cellular stressors may
also explain the contrasting results reported in the literature. Several other studies have indicated
that taurine [33,56,57] and its more potent derivative taurine chloramine [31,58,59] enhance Hmox1
expression through induction of the transcription factor nuclear factor erythroid 2-related factor
2 (Nrf2).
The impact of taurine on the protein expression of representative iron-associated proteins was
determined via western blotting. Ferritin is the major iron storage protein in mammals and consists
of 24 subunits and two isoforms, the light chain ferritin (FTL) and the heavy chain ferritin (FTH).
FTH exerts ferroxidase activity and converts ferrous ions (Fe2+) into the storable ferric (Fe3+) form,
while FTL aids in iron nucleation [60]. The arrangement of the ferritin subunit assembly is species- and
tissue-specific [61]. Under the conditions investigated, taurine significantly increased the FTL protein
levels more than two-fold but did not affect FTH protein levels. Interestingly, FTL-rich ferritin has been
shown to accumulate more iron ions than FTH-rich ferritin [62]. Thus, the cellular storage capacity for
iron may be augmented in taurine-supplemented cells, suggesting the prevention of accumulating
excess labile iron. Moreover, the higher the proportion of protein-associated iron, the lower the LIP and,
consequently, the extent of LPO [63,64]. Interestingly, Epsztejn et al. demonstrated that the reduction of
LIP through ferritin was accompanied by a decrease in cellular glutathione content [63]. Furthermore,
iron(II)glutathione was shown to be the dominant component of the labile iron pool [65]. Likewise,
in our study, supplementation with taurine significantly reduced total glutathione levels in muscle cells.
Cellular LIP is sensed and regulated by iron responsive element-binding proteins (IRPs),
which regulate ferritin and transferrin post-transcriptionally [66]. At low cellular labile iron levels,
IRPs bind to iron-responsive elements (IREs) within the mRNA of the two ferritin isoforms and inhibit
their translation. In contrast, binding of IRP to IRE of the Tfr mRNA inhibits its degradation and
enhances transferrin translation and thus cellular iron uptake [67]. This may explain the higher Ftl
and lower Tfr mRNA levels observed in our study in response to iron treatment (Figure 2B). Ftl and
Fth were not different after taurine supplementation, while the protein concentration of FTL was
significantly increased. It may be hypothesized that taurine supplementation modulated proteasomal
FTL degradation in a regulatory mechanism that was independent of its transcript level, which has
been described earlier [66,68]. Taken together, the regulation of IRP-induced modulation of LIP through
taurine supplementation seems plausible and holds great potential for future studies.
Cellular iron exists beyond the free (LIP) in stored (ferritin) forms, which is crucial for the synthesis
of iron-dependent proteins such as heme or iron-sulfur (Fe-S) cluster proteins. In our study, the levels of
the heme proteins myoglobin and cytochrome c were significantly higher after taurine supplementation.
This may further emphasize the shifting of cellular iron from labile forms to stored forms and protein
association in response to taurine supplementation. In vivo, the majority of iron is bound to the heme
protein hemoglobin in red blood cells, and there is evidence for a regulative role for taurine in this
process. Oral iron treatment for iron-deficiency and anemia in women was more effective when taurine
was co-supplemented [69], and circulating taurine was positively correlated with the amount of red
blood cells in female endurance athletes [70].
Other mitochondrial proteins that require iron for assembly, including the Fe-S cluster proteins of
the respiratory chain, were not affected by taurine. The mRNA level of Nupbl was increased, although
it was the only gene affected among the tested genes that encoded mitochondrial Fe-S cluster proteins.
To date, taurine has been suggested to affect the protein synthesis of the mitochondrially encoded
subunits mt-ND5 and mt-ND6 [34]. It remains unclear whether taurine may modulate Fe-S protein
cluster synthesis systematically and thereby modulate mitochondrial function.
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5. Conclusions
We provide evidence that taurine treatment of cells, which rely on exogenous taurine supply,
reduces the extent of LPO, which we assume is caused by shifting of cellular iron from free to
protein-associated forms. The involvement of labile iron pool sensing proteins and the role of taurine
in mitochondrial Fe-S cluster protein synthesis and respiratory function warrant further investigation.
It would be also interesting to validate the effect of taurine in cells and tissues with high iron stores
and/or substantial iron metabolism, such as hepatocytes or osteoblasts. Moreover, tissue taurine
levels, including skeletal muscle, are often diminished in aged versus young control animals [16–20].
Therefore, future studies should address the questions, whether dietary taurine supplementation
affects redox- and iron-homeostasis during the aging process.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-3921/9/11/1071/s1,
Figure S1: Western blots of three independent experiments showing the protein load of the membrane and the
respective target bands of the (a) taurine transporter (TAUT) at 140 kDa, (b) ferritin light chain (FTL) at 19 kDa,
(c) ferritin heavy chain (FTH) at 21 kDa, (d) myoglobin (MB) at 17 kDa, (e) Cytochrom C (CYTC) at 15 kDa
and (f) subunits of mitochondrial oxidative phosphorylation (OXPHOS) complexes CI (NADH dehydrogenese),
CII (succinate dehydrogenase), CIII (ubiquinol-cytochrome c reductase), CIV (cytochrome c oxidase) and CV
(ATP-Synthase) in response to control medium-(CON) and taurine-(TAUR) treatment.
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